cardinal health glp-1 receptor agonist weight management diabetes treatments GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon GLP-1 Medications Infographic | Medidex
Description
As of April 30, 2025, there had been 520 reports involving compounded semaglutide and 480 for compounded tirzepatide
The growing popularity of GLP-1 receptor agonistsincluding Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lillyhas added fuel to an already fiery debate over the governments role in subsidizing access to these drugs
One concern exists
[DOI] [PubMed] [Google Scholar] 38.Hesp AC, et al
Preprint at medRxiv (2023)
Insulin resistance and hyperinsulinemia are often present in obese individuals and play a significant role in the genesis of hypertension (112, 113)
